| 1 |
Ehrmann S, Barbier F, Demiselle J, Quenot JP, Herbrecht JE, Roux D, et al. Inhaled amikacin to prevent ventilator-associated pneumonia. N Engl J Med. 2023; 389(22):2052-62.
|
| 2 |
Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017; 36(11):1999-2006.
|
| 3 |
Rosenthal VD, Jin ZL, Yin RJ, Sahu S, Rajhans P, Kharbanda M, et al. Assessing the impact of a multidimensional approach and an 8-component bundle in reducing incidences of ventilator-associated pneumonia across 35 countries in Latin America, Asia, the Middle East, and Eastern Europe. J Crit Care. 2024; 80:154500.
|
| 4 |
Forel JM, Voillet F, Pulina D, Gacouin A, Perrin G, Barrau K, et al. Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy. Crit Care. 2012; 16(2):R65.
|
| 5 |
Martin-Loeches I, Povoa P, Nseir S. Ventilator associated tracheobronchitis and pneumonia: one infection with two faces. Intensive Care Med. 2023; 49(8):996-9.
doi: 10.1007/s00134-023-07086-9
pmid: 37160828
|
| 6 |
Martin-Loeches I, Reyes LF, Nseir S, Ranzani O, Povoa P, Diaz E, et al. European Network for ICU-Related Respiratory Infections (ENIRRIs): a multinational, prospective, cohort study of nosocomial LRTI. Intensive Care Med. 2023; 49(10): 1212-22.
doi: 10.1007/s00134-023-07210-9
pmid: 37812242
|
| 7 |
Ehrmann S, Chastre J, Diot P, Lu Q. Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care. Ann Intensive Care. 2017; 7(1):78.
doi: 10.1186/s13613-017-0301-6
pmid: 28766281
|
| 8 |
Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012; 38(2):263-71.
doi: 10.1007/s00134-011-2420-0
pmid: 22147112
|
| 9 |
Athanassa ZE, Markantonis SL, Fousteri MZF, Myrianthefs PM, Boutzouka EG, Tsakris A, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012; 38(11):1779-86.
doi: 10.1007/s00134-012-2628-7
pmid: 22810779
|
| 10 |
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111.
|
| 11 |
Rello J, Solé-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2017; 23(9):629-39.
|
| 12 |
Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017; 50(3):1700582.
|
| 13 |
Ehrmann S, Roche-Campo F, Bodet-Contentin L, Razazi K, Dugernier J, Trenado-Alvarez J, et al. Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients. Intensive Care Med. 2016; 42(2):192-201.
doi: 10.1007/s00134-015-4114-5
pmid: 26602786
|
| 14 |
Zha SS, Niu JY, He ZF, Fu W, Huang QY, Guan LL, et al. Prophylactic antibiotics for preventing ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis. Eur J Med Res. 2023; 28(1):348.
doi: 10.1186/s40001-023-01323-z
pmid: 37715208
|
| 15 |
Centers for Disease Control and Prevention. Ventilator-associated events (VAE). Available at: https://www.cdc.gov/nhsn/acute-care-hospital/vae
|
| 16 |
Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013; 13(8):665-71.
doi: 10.1016/S1473-3099(13)70081-1
pmid: 23622939
|
| 17 |
Li J, Liu K, Lyu S, Jing GQ, Dai B, Dhand R, et al. Aerosol therapy in adult critically ill patients: a consensus statement regarding aerosol administration strategies during various modes of respiratory support. Ann Intensive Care. 2023; 13(1):63.
|
| 18 |
Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C, et al. Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv. 2020; 33(6):300-4.
|
| 19 |
Dugernier J, Le Pennec D, Maerckx G, Allimonnier L, Hesse M, Castanares-Zapatero D, et al. Inhaled drug delivery: a randomized study in intubated patients with healthy lungs. Ann Intensive Care. 2023; 13(1):125.
doi: 10.1186/s13613-023-01220-y
pmid: 38072870
|
| 20 |
Le Guellec S, Pardessus J, Bodier-Montagutelli E, L’Hostis G, Dalloneau E, Piel D, et al. Administration of bacteriophages via nebulization during mechanical ventilation: in vitro study and lung deposition in macaques. Viruses. 2023; 15(3):602.
|
| 21 |
Sécher T, Heuzé-Vourc’h N. Barriers for orally inhaled therapeutic antibodies. Expert Opin Drug Deliv. 2023; 20(8):1071-84.
|
| 22 |
López-Gálvez R, Fleurot I, Chamero P, Trapp S, Olivier M, Chevaleyre C, et al. Airway administration of flagellin regulates the inflammatory response to Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2021; 65(4):378-89.
|
), Jie Li3
